A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON)
A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.
Sponsor: AstraZeneca
Listed as NCT01602380, this PHASE3 trial focuses on Hormone Receptor Positive Breast Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 35 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
35 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 30 earlier versions
-
Dec 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbotsford, Canada , Airdrie, United Kingdom , Ankara, Turkey (Türkiye) , Auburn, United States , Avellino, Italy , Bardejov, Slovakia , Bari, Italy , Barnaul, Russia , Benevento, Italy , Bratislava, Slovakia and 87 more locations